Mexidol® and Mexidol® FORTE 250: Just Go Ahead to New Efficacy and Safety Data!

LLC “Scientific Production Company “PHARMASOFT”, the owner of intellectual property for Mexidol® and Mexidol® Forte 250 reference (original) drugs, announces that it has obtained permission to conduct international randomized trials:

– A prospective international multicenter, randomized, double blind, placebo-controlled, parallel-group trial to evaluate the efficacy and safety of Mexidol® intravenous and intramuscular administration solution, 50 mg/ml, and 250 mg film-coated tablets Mexidol® FORTE with their sequential use in patients with acute and early restorative periods of ischemic stroke. Record No. PHS-APIS-004-MEX-SOL-TAB of 21.06.2019.

– An international multicenter, randomized, double blind, placebo-controlled, adaptive design study to evaluate the efficacy and safety of sequential therapy with Mexidol® solution for intravenous and intramuscular administration, 50 mg/ml, and Mexidol® FORTE 250 film-coated tablets, 250 mg in patients with chronic brain ischemia. Record No. PHS-CICADIS-005-MEX-SOL-TAB of 08.08.2019.